Ampyra dalfampridine: Phase II started

In December, Acorda began a double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate a single dose of 10 mg oral dalfampridine in about 50 patients. Dalfampridine is marketed in th...